Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $89.1 million.

  • Agios Pharmaceuticals' Cash & Equivalents rose 1689.64% to $89.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $89.1 million, marking a year-over-year increase of 1689.64%. This contributed to the annual value of $89.1 million for FY2025, which is 1689.64% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Cash & Equivalents stood at $89.1 million for Q4 2025, which was up 1689.64% from $92.7 million recorded in Q3 2025.
  • Agios Pharmaceuticals' 5-year Cash & Equivalents high stood at $1.9 billion for Q1 2021, and its period low was $64.3 million during Q3 2023.
  • In the last 5 years, Agios Pharmaceuticals' Cash & Equivalents had a median value of $90.9 million in 2025 and averaged $255.4 million.
  • In the last 5 years, Agios Pharmaceuticals' Cash & Equivalents surged by 201916.2% in 2021 and then plummeted by 9576.14% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Cash & Equivalents (Quarter) stood at $203.1 million in 2021, then tumbled by 31.44% to $139.3 million in 2022, then crashed by 36.66% to $88.2 million in 2023, then dropped by 13.56% to $76.2 million in 2024, then grew by 16.9% to $89.1 million in 2025.
  • Its Cash & Equivalents was $89.1 million in Q4 2025, compared to $92.7 million in Q3 2025 and $80.9 million in Q2 2025.